Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells and Hu14.18-IL2 in Neuroblastoma and Osteosarcoma
NCT03209869Phase 1Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2018
- Primary completion
- Sep 2022
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of haploidentical natural killer cells and Lorukafusp alfa in neuroblastoma and osteosarcoma (OS), sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of any grade acute or chronic GVHD. Planned start Mar 2018; status: withdrawn.
02
Drugs
haploidentical natural killer cellsLorukafusp alfa
03
Conditions
neuroblastomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT03209869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209869.